31.05.2013 - Genmab's and GSK's CD20 antibody ofatumumab challenges Roches
glyco-optimised obinutuzumab as treatment for CCL patients.
According to data presented by the Danish-British partnership, a combination therapy of ofatuzumab (Arzerra) and chlorambucil significantly improved median progression-free survival of patients with chronic lymphocytic leukaemia (CLL). Patients treated with the combination lived 22.4 months on average without the disease worsening. That is 9.3 months more than in patients receiving the chemotherapeutic alone (13.1 months; Hazard Ratio 0.57; p<0.001).
Two weeks prior to that, Roche had also met the primary endpoint of a Phase III study demonstrating a 12 months PFS benefit (23 months vs 10.9 months, HR=0.14, 95% CI 0.09-0.21, p <.0001) of a combination of obinutuzumab + chlorambucil compared to chemotherapy alone.
According to Genmab, serious adverse events were in the expected range with 3% of serious infusion reactions. Although not being statistically significant at this point in time, Roche published data indicating a higher rate of first-contact infusion reactions than observed after injections of the company's blockbuster rituximab.CLL is the most common form of leukaemia in adults. At present, no curative therapy is available.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.
08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.